Hanall Biopharma Capital Reinvestment Ratio
Hanall Biopharma capital reinvestment ratio. Hanall Biopharma (009420) has a Capital Reinvestment Ratio of 0.45x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩7.34 Billion) in capital expenditures (₩3.27 Billion). See 009420 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Hanall Biopharma (2011–2024)
Capital reinvestment ratio of Hanall Biopharma from 2011 to 2024. This chart tracks Hanall Biopharma's Capital Reinvestment Ratio across 10 annual periods. See financial flexibility index of Hanall Biopharma to measure the company's free cash flow as a share of total liabilities.
Hanall Biopharma Capital Reinvestment Ratio by Year (2011–2024)
Hanall Biopharma capital reinvestment ratio by year from 2011 to 2024. For the full cash flow conversion analysis, see 009420 operating cash flow.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.46x | ₩9.36 Billion | ₩23.07 Billion | ▲ +694.3% |
| 2023 | 0.31x | ₩29.64 Billion | ₩9.20 Billion | ▲ +176.3% |
| 2022 | 0.11x | ₩25.20 Billion | ₩2.83 Billion | ▼ -98.0% |
| 2021 | 5.48x | ₩839.87 Million | ₩4.61 Billion | ▲ +98.9% |
| 2020 | 2.76x | ₩929.29 Million | ₩2.56 Billion | ▲ +2561.8% |
| 2019 | 0.10x | ₩20.49 Billion | ₩2.12 Billion | ▲ +152.7% |
| 2017 | 0.04x | ₩42.14 Billion | ₩1.73 Billion | ▼ -96.0% |
| 2016 | 1.02x | ₩3.95 Billion | ₩4.03 Billion | ▲ +2.6% |
| 2012 | 0.99x | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩7.41 Billion | ₩426.70 Million | — |